Insulet Corp. stock plunges 12.5 percent and underperforms competitors

7 articles · Updated · MarketWatch · Apr 29

Shares closed at $160.02 on Wednesday, down for the fifth consecutive day, with trading volume surging to 4 million, far above the 50-day average.
Insulet's stock finished 54.91% below its 52-week high of $354.88, reached in November 2025, amid a generally weak market session.
Major competitors Eli Lilly, DexCom, and Johnson & Johnson also saw declines, but Insulet's drop was more severe, reflecting broader market pressures.

As Insulet falters from its device recall, which rival is poised to seize its market leadership?

Analysts are downgrading Insulet, yet insiders are buying. Who is right about the company's future?

Does Insulet's crisis reveal a fatal flaw in the med-tech industry's race for rapid innovation?

After hundreds of injuries from a silent defect, can Insulet regain the trust of its users?

With its flagship product under fire, can the upcoming Omnipod 6 save the company's reputation?